According to this study, the global Natural Killer (NK) Cell Therapeutics market size will reach US$ 340 million by 2031.

Cell therapy, a new therapeutic approach that uses a patients own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the bodys first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.

Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).

Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.

LPI (LP Information) newest research report, the Natural Killer (NK) Cell Therapeutics Industry Forecast looks at past sales and reviews total world Natural Killer (NK) Cell Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Natural Killer (NK) Cell Therapeutics sales for 2025 through 2031. With Natural Killer (NK) Cell Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Natural Killer (NK) Cell Therapeutics industry.

This Insight Report provides a comprehensive analysis of the global Natural Killer (NK) Cell Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Natural Killer (NK) Cell Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Natural Killer (NK) Cell Therapeutics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Natural Killer (NK) Cell Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Natural Killer (NK) Cell Therapeutics.

This report presents a comprehensive overview, market shares, and growth opportunities of Natural Killer (NK) Cell Therapeutics market by product type, application, key players and key regions and countries.

Segmentation by Type:

    Mogamulizumab
    Lorvotuzumab Mertansine
    Others

Segmentation by Application:

    Cancer
    Cardiovascular Diseases
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the companys coverage, product portfolio, its market penetration.

    Chipscreen Biosciences
    Affimed NV
    Altor BioScience
    Innate Pharma
    Takeda
    Sorrento Therapeutics
    NantKwest
    Bristol-Myers Squibb
    NKT
    Henry Ford Health Services